These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39156358)

  • 1. A Case Report of Pembrolizumab-Induced Allergic Hepatitis.
    Nakatani S; Fukushima M; Akahani S
    Cureus; 2024 Jul; 16(7):e64703. PubMed ID: 39156358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
    Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
    Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report.
    Otsuka T; Hashii Y; Murayama S; Ishizuka Y; Kojitani Y; Nishio M; Kudo T
    Front Oncol; 2023; 13():1164236. PubMed ID: 37251947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint-inhibitor pneumonitis: A case report and literature review.
    Nair DR; Trehan R
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1778. PubMed ID: 36601913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Hepatitis E Infection during Chemotherapy for Lung Cancer: A Case Report.
    Okumura H; Miyamoto A; Suzuki F; Takaya H
    Chemotherapy; 2023; 68(3):155-159. PubMed ID: 37166305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.
    Thapa A; Cowell A; Peters A; Noble DJ; James A; Lamb C; Grose D; Vohra S; Schipani S; Mactier K; Mackenzie J; Srinivasan D; Laws K; Moleron R; Niblock P; Soh FY; Paterson C; Wilson C
    Clin Oncol (R Coll Radiol); 2024 May; 36(5):287-299. PubMed ID: 38395634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report.
    Iijima H; Sakai A; Ebisumoto K; Yamauchi M; Teramura T; Yamazaki A; Inagi T; Okami K
    J Med Case Rep; 2023 Sep; 17(1):387. PubMed ID: 37697390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-Induced Delayed-Onset Hepatitis.
    Kanaoka K; Moriizumi K; Okada H; Iwahashi K; Tsuji H; Yasuoka H; Minami S
    Case Rep Gastroenterol; 2020; 14(3):586-592. PubMed ID: 33250701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near complete response to a pembrolizumab-based therapeutic strategy in an abdominal metastatic head and neck squamous cell carcinoma case.
    Wu T; Liang F; Lin P; Li Y; Huang X; Han P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2093075. PubMed ID: 35878084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-induced nephrotoxicity in a patient with breast cancer.
    Alkassis S; Fitzsimmons K; Hurvitz S
    Ther Adv Med Oncol; 2024; 16():17588359241248362. PubMed ID: 38680292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report.
    Sasaki K; Kobayashi S; Kudo M; Sugimoto M; Takahashi S; Nakamura Y; Kawazoe A; Shitara K; Kinoshita T; Gotohda N
    Surg Case Rep; 2021 Dec; 7(1):267. PubMed ID: 34928436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
    J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.